CytomX Therapeutics (CTMX) Other Accumulated Expenses (2014 - 2026)

CytomX Therapeutics has reported Other Accumulated Expenses for 13 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 1698.41% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 1698.41% YoY), and the FY2025 full-year result was $142000.0, down 71.02% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.1 million, up from $142000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.1 million in Q1 2026, with the low at $63000.0 in Q1 2025.
• Historically, Other Accumulated Expenses has averaged $349176.5 across 5 years, with a median of $292000.0 in 2024.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses slumped 86.15% — and 2026, when it surged 1698.41%.
• CytomX Therapeutics' Other Accumulated Expenses stood at $261000.0 in 2022, then grew by 20.31% to $314000.0 in 2023, then jumped by 56.05% to $490000.0 in 2024, then sank by 71.02% to $142000.0 in 2025, then soared by 697.89% to $1.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.1 million (Q1 2026), $142000.0 (Q4 2025), and $341000.0 (Q3 2025), per Business Quant data.